Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Stifel lowered its price target on Klaviyo to $35 from $40 with a Buy rating. The firm noted that the company delivered a ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results